Oppenheimer downgrades Integer on macroeconomic uncertainty

Oppenheimer downgraded Integer (ITGR) to Perform from Outperform without a price target following the Q4 report. While “fundamentally constructive” given Integer’s “diversified exposure to high-growth” medical technology segments, the downgrade is a reflection of the stock being at the prior price target and the uncertainty around possible tariff-induced structural dislocations, the analyst tells investors in a research note. The firm is taking a “wait and see stance” on the shares given the macroeconomic uncertainty related to tariffs.